using previously reported primers. 3, 4 The median percentage of tumor lymphocytes in patient samples was 74% (37-99%, range) as assessed with immunophenotype analysis (n ¼ 69). Residual normal cells did not significantly affect the determination of MCL-1 mRNA, since there was no difference in MCL-1 levels between the samples with 474% tumor purity and those with o74% purity (Kruskall-Wallis test, P ¼ 0.41, NS). In 18 samples, we quantified MCL-1 protein expression using flow cytometry and found that the mRNA and protein levels were significantly correlated (Figure 1) , suggesting that the amount of MCL-1 mRNA was predictive of the MCL-1 protein expression.
The MCL-1/GUS ratio was highly variable within a range of 10-776, with a median value of 85. We scored the relative level of MCL-1 mRNA as low (first tertile, o55), intermediate (second tertile, 55-133) and high (third tertile, 4133) and compared the survival in these groups. The survival times were not different in patients with intermediate and high MCL-1 expression (log-rank test, P ¼ 0.78). However, patients expressing MCL-1 at intermediate/high levels (X55) have significantly shorter survival than patients expressing MCL-1 at low levels (o55). This relationship was significant within the whole patient population (P ¼ 0.00092; Figure 2a ) and among stage A patients (P ¼ 0.002; Figure 2b ). Moreover, the time to first therapy was significantly shorter in previously untreated stage A patients with intermediate/high levels of MCL-1 mRNA compared with those with low levels of MCL-1 mRNA (P ¼ 0.00088; Figure 2c ).
In a multivariate Cox analysis with the major prognostic indicators of B-CLL, 5 Binet stage (P ¼ 0.013) and immunoglobulin V gene (IgV) mutational status (P ¼ 0.0014), MCL-1 mRNA expression was an independent, significant predictor of overall survival (P ¼ 0.0093). The hazard ratio for higher MCL-1 expression (X55) was 7.0 (95% confidence interval 1.6-30.6).
In addition, MCL-1 mRNA levels did not correlate with clinical stage and known biological prognostic markers of B-CLL 5 such as IgV mutational status (n ¼ 87), CD38 expression (n ¼ 69), serum thymidine kinase (n ¼ 62) and b2-microglobulin (n ¼ 63) levels, lymphocyte doubling time (n ¼ 64) and human telomerase reverse-transcriptase mRNA expression (n ¼ 113) (data not shown).
MCL
We also determined the levels of BCL-2 gene expression using RQ-PCR 6 in the whole B-CLL cohort. The BCL-2/GUS ratio varied between 15 and 1780 with a median of 385. The level of BCL-2 expression was on average fivefold higher than the level of MCL-1 mRNA (Kruskall-Wallis test, Po10 À7 ). The expression of BCL-2 was less variable (82%, coefficient of variation) than the expression of MCL-1 (105%, coefficient of variation). Of note, the levels of BCL-2 and MCL-1 transcripts were significantly correlated (Spearman's rank test, r ¼ 0.42, P ¼ 0.000016). To assess the relative prognostic importance of BCL-2 and MCL-1 transcript levels, we included these two parameters in a Cox model for overall survival. MCL-1 (P ¼ 0.0092) but not BCL-2 gene expression (P ¼ 0.52) had a significant impact on prognosis. In a previous study, BCL-2 mRNA was found to be overexpressed in most of the B-CLL samples and alone was not predictive of patient outcome. 7 The current study shows that the level of MCL-1 mRNA expression may be an independent prognostic marker in B-CLL, which is not correlated to traditional indicators of prognosis such as IgV gene mutation profile. In particular, a low MCL-1 gene expression identifies stage A patients with indolent and stable disease and a longer time interval between diagnosis and need of therapy. Lower levels of MCL-1 protein expression have been previously correlated with the ability of patients with B-CLL to achieve a complete remission after treatment.
1 Of note, our data suggest that the MCL-1 mRNA and protein levels in B-CLL are correlated. Taken together, these observations show that low MCL-1 expression levels characterize B-CLL patients with a low risk of disease progression who also are likely to respond to treatment, which may be useful for the therapeutic management of cases with early B-CLL.
In the future prospective studies, it would be important to validate these results and explore if the MCL-1 transcript level is predictive of a treatment response. It would also be essential to investigate in individual patients whether the MCL-1 expression level remains stable during the course of the disease or increases during progression or development of drug resistance.
The prognostic role of MCL-1 gene expression further implicates this pro-survival molecule in the pathogenesis of B-CLL. Given that most B-CLL cells contain high levels of BCL-2, it was suggested that the combination of MCL-1 and BCL-2 might provide a superior protection against apoptosis. 8 Of note, BCL-2 and MCL-1 can inhibit apoptosis by sequestering prodeath proteins. Del Gaizo Moore et al. 8 have recently observed that in B-CLL cells almost all pro-apoptotic BIM appeared to be present in complex with BCL-2. They suggested that in B-CLL cells with abundant BCL-2, this protein is so highly occupied by BIM molecules that the cells have very poor anti-apoptotic reserve, which may potentially explain the notable chemosensitivity of B-CLL. Upregulation of the MCL-1 gene might provide additional survival capacities to B-CLL cells during physiological stress or drug treatment. Specific downregulation of MCL-1 gene expression by short interfering RNA has been recently shown to reduce the MCL-1 protein level and promote apoptosis and death of primary B-CLL cells. 2 In this regard, our finding that low MCL-1 gene expression is related to a good prognosis may be relevant, supporting MCL-1 as a potential therapeutic target. However, it should be noted that the downregulation of MCL-1 influences only some of the death pathways and eliminates only a proportion of B-CLL cells. Targeting MCL-1 expression in B-CLL could be effective in combination with other antitumor agents such as rituximab. 
